Last reviewed · How we verify
Mitomycin C (MMC)
Mitomycin C is an alkylating agent that cross-links DNA strands, preventing cell division and triggering cancer cell death.
Mitomycin C is an alkylating agent that cross-links DNA strands, preventing cell division and triggering cancer cell death. Used for Gastric cancer, Pancreatic cancer, Colorectal cancer.
At a glance
| Generic name | Mitomycin C (MMC) |
|---|---|
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Drug class | Alkylating agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
MMC is a naturally derived antibiotic that acts as a bifunctional alkylating agent. After metabolic activation, it covalently binds to DNA and forms inter- and intra-strand cross-links, blocking DNA replication and transcription. This leads to cell cycle arrest and apoptosis, making it effective against rapidly dividing cancer cells.
Approved indications
- Gastric cancer
- Pancreatic cancer
- Colorectal cancer
- Bladder cancer (intravesical)
Common side effects
- Myelosuppression (thrombocytopenia, leukopenia, anemia)
- Nausea and vomiting
- Mucositis
- Hemolytic uremic syndrome
- Pulmonary toxicity
- Nephrotoxicity
Key clinical trials
- Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (PHASE2)
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies (PHASE1)
- Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial (PHASE2)
- Preserflo MicroShunt Versus Trabeculectomy (NA)
- Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer (PHASE3)
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors (PHASE1)
- Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mitomycin C (MMC) CI brief — competitive landscape report
- Mitomycin C (MMC) updates RSS · CI watch RSS
- Memorial Sloan Kettering Cancer Center portfolio CI